Free Trial

AstraZeneca (AZN) Competitors

AstraZeneca logo
$70.49 -1.30 (-1.81%)
As of 11:09 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AZN vs. NVO, NVS, SNY, GSK, TAK, ARGX, BNTX, ONC, SMMT, and TEVA

Should you be buying AstraZeneca stock or one of its competitors? The main competitors of AstraZeneca include Novo Nordisk A/S (NVO), Novartis (NVS), Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), argenx (ARGX), BioNTech (BNTX), Beigene (ONC), Summit Therapeutics (SMMT), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical products" industry.

AstraZeneca vs.

Novo Nordisk A/S (NYSE:NVO) and AstraZeneca (NASDAQ:AZN) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation, earnings and community ranking.

Novo Nordisk A/S received 371 more outperform votes than AstraZeneca when rated by MarketBeat users. Likewise, 61.74% of users gave Novo Nordisk A/S an outperform vote while only 60.00% of users gave AstraZeneca an outperform vote.

CompanyUnderperformOutperform
Novo Nordisk A/SOutperform Votes
434
61.74%
Underperform Votes
269
38.26%
AstraZenecaOutperform Votes
63
60.00%
Underperform Votes
42
40.00%

In the previous week, Novo Nordisk A/S had 16 more articles in the media than AstraZeneca. MarketBeat recorded 55 mentions for Novo Nordisk A/S and 39 mentions for AstraZeneca. AstraZeneca's average media sentiment score of 1.04 beat Novo Nordisk A/S's score of 0.62 indicating that AstraZeneca is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novo Nordisk A/S
27 Very Positive mention(s)
7 Positive mention(s)
11 Neutral mention(s)
5 Negative mention(s)
3 Very Negative mention(s)
Positive
AstraZeneca
17 Very Positive mention(s)
3 Positive mention(s)
10 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Novo Nordisk A/S has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500.

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 20.4% of AstraZeneca shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Novo Nordisk A/S pays an annual dividend of $1.63 per share and has a dividend yield of 2.5%. AstraZeneca pays an annual dividend of $2.06 per share and has a dividend yield of 2.9%. Novo Nordisk A/S pays out 49.5% of its earnings in the form of a dividend. AstraZeneca pays out 91.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Novo Nordisk A/S presently has a consensus target price of $135.00, suggesting a potential upside of 102.92%. AstraZeneca has a consensus target price of $88.00, suggesting a potential upside of 22.58%. Given Novo Nordisk A/S's higher probable upside, equities research analysts plainly believe Novo Nordisk A/S is more favorable than AstraZeneca.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novo Nordisk A/S
2 Sell rating(s)
5 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.38
AstraZeneca
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
3.10

Novo Nordisk A/S has a net margin of 34.81% compared to AstraZeneca's net margin of 13.01%. Novo Nordisk A/S's return on equity of 84.68% beat AstraZeneca's return on equity.

Company Net Margins Return on Equity Return on Assets
Novo Nordisk A/S34.81% 84.68% 26.29%
AstraZeneca 13.01%32.23%12.31%

Novo Nordisk A/S has higher revenue and earnings than AstraZeneca. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novo Nordisk A/S$290.40B1.03$14.64B$3.2920.22
AstraZeneca$54.07B4.12$7.04B$2.2631.77

Summary

Novo Nordisk A/S beats AstraZeneca on 13 of the 21 factors compared between the two stocks.

Get AstraZeneca News Delivered to You Automatically

Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AZN vs. The Competition

MetricAstraZenecaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$222.64B$6.89B$5.56B$7.82B
Dividend Yield2.96%3.05%5.11%4.22%
P/E Ratio31.777.4422.5118.48
Price / Sales4.12242.70395.68103.60
Price / Cash11.7965.8538.1834.62
Price / Book5.456.516.774.25
Net Income$7.04B$143.21M$3.22B$248.23M
7 Day Performance3.22%1.98%1.45%0.89%
1 Month Performance-1.12%6.89%3.97%3.53%
1 Year Performance-6.05%-2.52%16.14%5.08%

AstraZeneca Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AZN
AstraZeneca
3.6197 of 5 stars
$70.49
-1.8%
$88.00
+24.8%
-5.4%$218.17B$54.07B31.1383,500Earnings Report
Short Interest ↓
Analyst Revision
Positive News
Gap Down
NVO
Novo Nordisk A/S
4.6323 of 5 stars
$62.33
+0.4%
$135.00
+116.6%
-48.1%$279.47B$290.40B18.9354,400Upcoming Earnings
Analyst Upgrade
Short Interest ↑
Gap Up
NVS
Novartis
2.4586 of 5 stars
$112.84
+0.6%
$123.38
+9.3%
+16.6%$238.25B$51.72B19.18101,700Earnings Report
Short Interest ↑
Positive News
SNY
Sanofi
3.4914 of 5 stars
$52.73
+0.8%
$63.33
+20.1%
+11.6%$133.19B$44.29B21.1791,600Earnings Report
Analyst Upgrade
Analyst Revision
Positive News
Gap Up
GSK
GSK
1.239 of 5 stars
$38.16
+1.9%
$40.58
+6.4%
-3.9%$78.70B$31.38B23.9990,100Earnings Report
Analyst Upgrade
News Coverage
TAK
Takeda Pharmaceutical
3.1745 of 5 stars
$15.15
+0.8%
N/A+16.8%$48.22B$4.58T37.8947,300Upcoming Earnings
News Coverage
Positive News
ARGX
argenx
3.2875 of 5 stars
$618.09
+0.5%
$699.28
+13.1%
+71.8%$37.60B$2.19B-699.69650Upcoming Earnings
Positive News
BNTX
BioNTech
2.5499 of 5 stars
$104.02
+2.0%
$143.44
+37.9%
+17.3%$24.99B$2.75B-49.583,080Upcoming Earnings
ONC
Beigene
2.0068 of 5 stars
$250.19
+2.2%
$318.88
+27.5%
N/A$24.74B$3.81B-30.369,000Analyst Forecast
Analyst Revision
SMMT
Summit Therapeutics
2.681 of 5 stars
$24.29
+3.5%
$37.50
+54.4%
+513.7%$17.99B$700,000.00-87.11110Analyst Forecast
Analyst Revision
Gap Down
High Trading Volume
TEVA
Teva Pharmaceutical Industries
3.2781 of 5 stars
$14.96
+0.6%
$23.43
+56.6%
+10.5%$16.95B$16.54B-10.3136,800Upcoming Earnings
Analyst Upgrade
Analyst Revision
Positive News

Related Companies and Tools


This page (NASDAQ:AZN) was last updated on 5/1/2025 by MarketBeat.com Staff
From Our Partners